SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study.

ABSTRACT:

SUBMITTER: Qin S 

PROVIDER: S-EPMC11337918 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature